Form 4: Inovio Pharmaceuticals' Chief Scientific Officer Reports Stock Transactions
SEC Form 4 Filing
Laurent Humeau, Chief Scientific Officer of Inovio Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On May 15, 2024, Laurent Humeau, the Chief Scientific Officer of Inovio Pharmaceuticals, had 4,771 restricted stock units vest.
- These units were settled for common stock.
- The company withheld 1,703 shares to cover Humeau's tax obligations at a price of $13.07 per share.
- Following these transactions, Humeau directly owns 24,337 shares of Inovio common stock and 9,542 restricted stock units.
- The restricted stock units vest in three tranches: 4,771 shares vested on May 15, 2024, with subsequent tranches vesting on May 15, 2025, and May 15, 2026.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company executive, and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Key Dates
| Date | Description |
|---|---|
| 01/24/2024 | Inovio effected a 1-for-12 reverse stock split. |
| 05/15/2024 | 4,771 restricted stock units vested for Laurent Humeau. |
| 05/15/2025 | 4,771 restricted stock units will vest for Laurent Humeau. |
| 05/15/2026 | 4,771 restricted stock units will vest for Laurent Humeau. |
| 05/16/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.